Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effects of sodium‐glucose co‐transporter 2 (SGLT2) inhibitors on serum uric acid level: A meta‐analysis of randomized controlled trials
Yumo Zhao, Lubin Xu, Dongli Tian, et al.
Diabetes Obesity and Metabolism (2017) Vol. 20, Iss. 2, pp. 458-462
Closed Access | Times Cited: 290

Showing 1-25 of 290 citing articles:

SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control
Martín Cowie, Miles Fisher
Nature Reviews Cardiology (2020) Vol. 17, Iss. 12, pp. 761-772
Closed Access | Times Cited: 572
Molecular Biological and Clinical Understanding of the Pathophysiology and Treatments of Hyperuricemia and Its Association with Metabolic Syndrome, Cardiovascular Diseases and Chronic Kidney Disease
Hidekatsu Yanai, Hiroki Adachi, Mariko Hakoshima, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 17, pp. 9221-9221
Open Access | Times Cited: 328
Renoprotective effects of sodium-glucose cotransporter-2 inhibitors
Hiddo J.L. Heerspink, Mikhail Kosiborod, Silvio E. Inzucchi, et al.
Kidney International (2018) Vol. 94, Iss. 1, pp. 26-39
Open Access | Times Cited: 324
Physiology of Hyperuricemia and Urate-Lowering Treatments
Caroline Benn, Vivek Dua, Rachel Gurrell, et al.
Frontiers in Medicine (2018) Vol. 5
Open Access | Times Cited: 269
Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: The potential contribution to diabetes complications and cardiovascular disease
Fabrice Bonnet, André Scheen
Diabetes & Metabolism (2018) Vol. 44, Iss. 6, pp. 457-464
Closed Access | Times Cited: 258
Cardiovascular Effects of New Oral Glucose-Lowering Agents
André Scheen
Circulation Research (2018) Vol. 122, Iss. 10, pp. 1439-1459
Open Access | Times Cited: 251
Uric Acid and Cardiovascular Disease: An Update From Molecular Mechanism to Clinical Perspective
Wei Yu, Jidong Cheng
Frontiers in Pharmacology (2020) Vol. 11
Open Access | Times Cited: 247
Sodium–glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus
André Scheen
Nature Reviews Endocrinology (2020) Vol. 16, Iss. 10, pp. 556-577
Closed Access | Times Cited: 228
Renal and Cardiovascular Effects of SGLT2 Inhibition in Combination With Loop Diuretics in Patients With Type 2 Diabetes and Chronic Heart Failure
Natalie Mordi, Ify Mordi, Jagdeep Singh, et al.
Circulation (2020) Vol. 142, Iss. 18, pp. 1713-1724
Open Access | Times Cited: 184
Uric acid and the cardio‐renal effects of SGLT2 inhibitors
Clifford J. Bailey
Diabetes Obesity and Metabolism (2019) Vol. 21, Iss. 6, pp. 1291-1298
Open Access | Times Cited: 158
Research Advances in the Mechanisms of Hyperuricemia-Induced Renal Injury
Hong-yong Su, Chen Yang, Dong Liang, et al.
BioMed Research International (2020) Vol. 2020, pp. 1-12
Open Access | Times Cited: 148
An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors
Teresa Salvatore, Raffaele Galiero, Alfredo Caturano, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 7, pp. 3651-3651
Open Access | Times Cited: 145
<p>Extraglycemic Effects of SGLT2 Inhibitors: A Review of the Evidence</p>
Benedetta Maria Bonora, Angelo Avogaro, Gian Paolo Fadini
Diabetes Metabolic Syndrome and Obesity (2020) Vol. Volume 13, pp. 161-174
Open Access | Times Cited: 139
Glomerular hyperfiltration
Monica Cortinovis, Norberto Perico, Piero Ruggenenti, et al.
Nature Reviews Nephrology (2022) Vol. 18, Iss. 7, pp. 435-451
Closed Access | Times Cited: 115
A kidney perspective on the mechanism of action of sodium glucose co-transporter 2 inhibitors
Taha Sen, Hiddo J.L. Heerspink
Cell Metabolism (2021) Vol. 33, Iss. 4, pp. 732-739
Open Access | Times Cited: 111
SGLT2 Inhibition and Uric Acid Excretion in Patients with Type 2 Diabetes and Normal Kidney Function
Danii L. S. Suijk, Michaël J.B. van Baar, Erik J.M. van Bommel, et al.
Clinical Journal of the American Society of Nephrology (2022) Vol. 17, Iss. 5, pp. 663-671
Open Access | Times Cited: 69
SGLT2 inhibitors: from glucose-lowering to cardiovascular benefits
Alberto Preda, Fabrizio Montecucco, Federico Carbone, et al.
Cardiovascular Research (2024) Vol. 120, Iss. 5, pp. 443-460
Open Access | Times Cited: 34
Sodium–glucose cotransporter 2 inhibitors for transthyretin amyloid cardiomyopathy: Analyses of short‐term efficacy and safety
Frederick Lang, Sergio Teruya, Ariel Weinsaft, et al.
European Journal of Heart Failure (2024) Vol. 26, Iss. 4, pp. 938-947
Closed Access | Times Cited: 18
Beneficial effects of SGLT2 inhibitors on fatty liver in type 2 diabetes: A common comorbidity associated with severe complications
André Scheen
Diabetes & Metabolism (2019) Vol. 45, Iss. 3, pp. 213-223
Closed Access | Times Cited: 126
Sodium–glucose co‐transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology
Petar Seferović, Gabriele Fragasso, Mark C. Petrie, et al.
European Journal of Heart Failure (2020) Vol. 22, Iss. 9, pp. 1495-1503
Open Access | Times Cited: 122
SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation
Katherine R. Tuttle, Frank C. Brosius, Matthew A. Cavender, et al.
American Journal of Kidney Diseases (2020) Vol. 77, Iss. 1, pp. 94-109
Open Access | Times Cited: 111
Effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate in patients with heart failure (Empire HF Renal): a prespecified substudy of a double-blind, randomised, placebo-controlled trial
J. Steen Jensen, Massar Omar, Caroline Kistorp, et al.
The Lancet Diabetes & Endocrinology (2020) Vol. 9, Iss. 2, pp. 106-116
Closed Access | Times Cited: 102
Autophagy-dependent and -independent modulation of oxidative and organellar stress in the diabetic heart by glucose-lowering drugs
Milton Packer
Cardiovascular Diabetology (2020) Vol. 19, Iss. 1
Open Access | Times Cited: 98
Impact of sodium glucose cotransporter 2 (SGLT2) inhibitors on atherosclerosis: from pharmacology to pre-clinical and clinical therapeutics
Zhenghong Liu, Xiaoxuan Ma, Iqra Ilyas, et al.
Theranostics (2021) Vol. 11, Iss. 9, pp. 4502-4515
Open Access | Times Cited: 98
SGLT2 inhibitors and cardioprotection: a matter of debate and multiple hypotheses
Theodosios D. Filippatos, Angelos Liontos, Ioanna Papakitsou, et al.
Postgraduate Medicine (2019) Vol. 131, Iss. 2, pp. 82-88
Closed Access | Times Cited: 96
Page 1 - Next Page

Scroll to top